"Today the CF Foundation announced the expansion of its collaboration with Vertex Pharmaceuticals to accelerate the discovery & development of new drugs aimed at treating the underlying cause of cystic fibrosis in those who have the most common CF mutation, Delta F508."
Learn more: CF Foundation Announces Investment to Speed Development of Additional Drugs to Treat the Most Common CF Mutation
Violet has two different defective gene mutations and one is the Delta F508, the most common. This new Vertex drug has shown great promise in clinical trials!
Make plans to attend the The UltraViolet Rock Show and Art Auction for CF ... We'll bring the rock and raise the funds... we're full speed ahead for finding a cure....
4.07.2011
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment